Nab-paclitaxel PIPAC with paclitaxel and ramucirumab for stomach cancer spread to belly lining
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stomach cancer (adenocarcinoma) that has spread to the lining of your belly, seen on a scan or during a laparoscopy.
- Your cancer must have gotten worse after at least one round of standard chemotherapy (like FOLFOX).
- You must be 18 or older and in good enough health to be up and about (ECOG 0 or 1).
- You cannot have had an allergic reaction to taxane drugs (like paclitaxel).
- You must have acceptable kidney, liver, and blood counts, and no uncontrolled infections or major heart or blood clot problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give the drug paclitaxel directly into your belly as a mist, along with two standard chemo drugs given through your veins, for bile duct or gallbladder cancer that has spread to the lining of the belly. The goal is to see if this approach can better control the cancer in the belly.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This study tests a treatment that combines chemotherapy given directly into the abdomen (intraperitoneal) with standard systemic chemotherapy for people whose gastrointestinal cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). It aims to control the cancer and improve how patients feel.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
Hear when a new Clinical Stage IVB Gastric Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.